Short Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Declines By 11.0%

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 25,000 shares, a decrease of 11.0% from the November 30th total of 28,100 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ? days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised Basilea Pharmaceutica to a “strong-buy” rating in a research note on Monday, September 23rd.

Basilea Pharmaceutica Price Performance

Shares of BPMUF stock remained flat at $52.83 on Tuesday. The business has a 50 day moving average price of $52.83 and a two-hundred day moving average price of $50.70. Basilea Pharmaceutica has a 1-year low of $38.60 and a 1-year high of $52.83.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.